Discussion
Encaleret increased bone turnover markers and improved patient-reported symptoms in people with autosomal dominant hypocalcemia type 1 (ADH1), a genetic form of hypoparathyroidism, in a Phase 3 trial. At 24 weeks, all participants receiving encaleret reported improvement in at least one ADH1 symptom, compared with 46% of those receiving…